Aminoglycosides: Activity and resistance

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 4, 1999, Pages 727-737

  Mingeot Leclercq, Marie Paule ^a   Glupczynski, Youri ^b   Tulkens, Paul M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXYSTREPTAMINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; DIBEKACIN; FORTIMICIN; GENTAMICIN; HABEKACIN; ISEPAMICIN; KANAMYCIN; NETILMICIN; PHOSPHOTRANSFERASE; SISOMICIN; STREPTIDINE; STREPTOMYCIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STRUCTURE ANALYSIS;

EID: 0032920402     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.4.727     Document Type: Short Survey

References (121)

1. Albert, R., K. Dax, A. E. Stütz, and J. Hildebrandt. 1985. Chemical modification of amikacin at C-4″ with inversion of configuration. J. Antibiot. (Tokyo) 38:275-278.
2. Bar-Nun, S., Y. Shneyour, and J. S. Beckman. 1983. G-418, an elongation inhibitor of 80 S ribosomes. Biochim. Biophys. Acta 741:123-127.
3. Benveniste, R., and J. Davies. 1973. Structure-activity relationships among the aminoglycoside antibiotics: role of hydroxyl and amino groups. Antimicrob. Agents Chemother. 4:402-409.
4. Brummett, R., and K. Fox. 1989. Aminoglycoside-induced hearing loss in humans. Antimicrob. Agents Chemother. 33:797-800.
5. Bryan, L. E., and S. Kwan. 1983. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin. Antimicrob. Agents Chemother. 23:835-845.
6. Buchanan, J. H., A. Stevens, and J. Sidhu. 1987. Aminoglycoside antibiotic treatment of human fibroblasts: intracellular accumulation, molecular changes and the loss of ribosomal accuracy. Eur. J. Cell Biol. 43:141-147.
7. Busse, H. J., C. Wostmann, and E. P. Bakker. 1992. The bactericidal action of streptomycin: membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of Escherichia coli and subsequent caging of the antibiotic inside the cells: degradation of these proteins. J. Gen. Microbiol. 138:551-561.
8. Chambers, H. F., and M. A. Sande. 1995. Antimicrobial agents: the aminoglycosides, p. 1103-1121. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, and A. Goodman Gilman (ed.), The pharmacological basis of therapeutics. McGraw-Hill, New York, N.Y.
9. Chaslus-Dancla, E., Y. Glupczynski, G. Gerbaud, M. Lagorce, J. P. Lafont, and P. Courvalin. 1989. Detection of apramycin resistant Enterobacteriaceae in hospital isolates. FEMS Microbiol. Lett. 61:261-266.
10. Chen, Q., R. H. Shafer, and I. D. Kuntz. 1997. Structure-based discovery of ligands targeted to the RNA double helix. Biochemistry 36:11402-11407.
11. Chung, L., G. Kaloyanides, R. McDaniel, A. McLaughlin, and S. McLaughin. 1985. Interaction of gentamicin and spermine with bilayer membranes containing negatively-charged phospholipids. Biochemistry 24: 442-452.
12. Cox, J. R., and E. H. Serpersu. 1997. Biologically important conformations of aminoglycoside antibiotics bound to an aminoglycoside 3′-phosphotransferase as determined by transferred nuclear Overhauser effect spectroscopy. Biochemistry 36:2353-2359.
13. Cox, J. R., G. A. McKay, G. D. Wright, and E. H. Serpersu. 1996. Arrangement of substrate at the active site of an aminoglycoside antibiotic 3′-phosphotransferase as determined by NMR. J. Am. Chem. Soc. 18:1295-1301.
14. Craig, W. A. 1993. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. 31(Suppl. D):149-158.
15. Daigle, D. M., G. A. McKay, and G. D. Wright. 1997. Inhibition of aminoglycoside antibiotic resistance enzymes by protein kinase inhibitors. J. Biol. Chem. 272:24755-24758.
16. Daikos, G. L., V. T. Lolans, and G. G. Jackson. 1991. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob. Agents Chemother. 35:117-123.
17. Davies, J., and A. Jimenez. 1980. A new selective agent for eukaryotic cloning vectors. Am. J. Trop. Med. Hyg. 29:1089-1092.
18. Davies, J., and G. D. Wright. 1997. Bacterial resistance to aminoglycoside antibiotics. Trends Microbiol. 5:234-240.
19. Dornbusch, K. 1987. European study group on antibiotic resistance. In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratories. Eur. J. Clin. Microbiol. 6:378-385.
20. Dornbusch, K., G. H. Miller, R. S. Hare, and K. J. Shaw. 1990. Resistance to aminoglycoside antibiotics in gram-negative bacilli and staphylococci isolated from blood. Report from a European collaborative study. J. Antimicrob. Chemother. 26:131-144.
21. Edgar, R., and E. Bibi. 1997. Mdfa, an Escherichia coli multidrug resistance protein with an extraordinarily broad spectrum of drug recognition. J. Bacteriol. 179:2274-2280.
22. Eustice, D. C., and J. M. Wilhelm. 1984. Mechanisms of action of aminoglycoside antibiotics in eukaryotic protein synthesis. Antimicrob. Agents Chemother. 26:53-60.
23. Fourmy, D., M. I. Recht, S. C. Blanchard, and J. D. Puglisi. 1996. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274:1367-1371.
24. Gates, C. A., and B. Northrop. 1988. Alternative substrate and inhibition kinetics of aminoglycoside nucleotidyltransferase 2″-I in support of a Theorell-Chance kinetic mechanism. Biochemistry 27:3826-3833.
25. Gates, C. A., and D. B. Northrop. 1988. Substrate specificities and structure-activity relationships for the nucleotidylation of antibiotics catalyzed by aminoglycoside nucleotidyltransferase 2″-I. Biochemistry 27:3820-3825.
26. Gates, C. A., and D. B. Northrop. 1988. Determination of the rate-limiting segment of aminoglycoside nucleotidyltransferase 2″-I by pH- and viscosity-dependent kinetics. Biochemistry 27:3834-3842.
27. Georgiadis, M. P., and V. Constantinou-Kokotou. 1991. Synthesis of amino acid derivatives of neamine and 2-deoxystreptamine to be used as mutasynthons. J. Carbohydr. Chem. 10:739-748.
28. Gilbert, D. N. 1995. Aminoglycosides, p. 279-306. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York, N.Y.
29. Gomez-Lus, R., S. Gomez-Lus, M. P. Goni, M. J. Rivera, C. Martin, and M. C. Rubio-Calvo. 1989. Stability of dactimicin to aminoglycoside-modifying enzymes produced by 341 bacterial clinical isolates. Drugs Exp. Clin. Res. 15:129-132.
30. Halaban, R., and F. D. Alfano. 1984. Selective elimination of fibroblasts from cultures of normal human melanocytes. In Vitro 20:447-450.
31. Hancock, R. E. W. 1981. Aminoglycoside uptake and mode of action - with special reference to streptomycin and gentamicin. I. Antagonists and mutants. J. Antimicrob. Chemother. 8:249-276.
32. Hancock, R. E., S. W. Farmer, Z. S. Li, and K. Poole. 1991. Interaction of aminoglycosides with the outer membranes and purified lipopolysaccharide and OmpF porin of Escherichia coli. Antimicrob. Agents Chemother. 35: 1309-1314.
33. Hayashi, S. F., L. J. Norcia, S. B. Seibel, and A. M. Silvia. 1997. Structure-activity relationships of hygromycin A and its analogs: protein synthesis inhibition activity in a cell free system. J. Antibiot. (Tokyo) 50:514-521.
34. Hidaka, H., M. Inagaki, S. Kawamoto, and Y. Sasaki. 1984. Isoquinoline-sulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23:5036-5041.
35. Hildebrandt, J., H. Loibner, E. Schütze, W. Streicher, P. Stütz, and A. Wenzel. 1984. Synthesis and biological properties of the aminoglycoside 87-351, a new standard in overcoming enzyme-mediated aminoglycoside resistance, abstr. 310. In Program and abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Holm, S. E., B. Hill, A. Lowestad, R. Maller, and A. Vikefors. 1983. A prospective, randomized study of amikacin and gentamicin in serious infections with focus on efficacy, toxicity and duration of serum levels above the MIC. J. Antimicrob. Chemother. 12:393-402.
37. Hon, W. C., G. A. McKay, P. R. Thompson, R. M. Sweet, D. S. Yang, G. D. Wright, and A. M. Berghuis. 1997. Structure of an enzyme required for aminoglycoside antibiotic resistance reveals homology to eukaryotic protein kinases. Cell 89:887-895.
38. Hotta, K., C. B. Zhu, T. Ogata, A. Sunada, J. Ishikawa, S. Mizuno, and S. Kondo. 1996. Enzymatic 2′-N-acetylation of arbekacin and antibiotic activity of its product. J. Antibiot. (Tokyo) 49:458-464.
39. Inoue, M., M. Nonoyama, R. Okamoto, and T. Ida. 1994. Antimicrobial activity of arbekacin, a new aminoglycoside antibiotic, against methicillin-resistant Staphylococcus aureus. Drugs Exp. Clin. Res. 20:233-239.
40. Inouye, Y., M. Hashimoto, M. Sugiyama, Y. Takesue, T. Santo, and T. Yokohama. 1994. Susceptibility of methicillin-resistant Staphylococcus aureus clinical isolates to various antimicrobial agents. IV. Aminoglycoside-modifying enzyme AAC(6′)-APH(2″) is responsible for arbekacin-resistance enhanced by bleomycin. Hiroshima J. Med. Sci. 43:87-92.
41. Johnson, A. P., M. Malde, N. Woodford, R. J. Cunney, and E. G. Smyth. 1995. Urinary isolates of apramycin-resistant Escherichia coli and Klebsiella pneumoniae from Dublin. Epidemiol. Infect. 114:105-112.
42. Karlowsky, J. A., D. J. Hoban, S. A. Zelenitsky, and G. G. Zhanel. 1997. Altered denA and anr gene expression in aminoglycoside adaptive resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 40:371-376.
43. Kawaguchi, H., T. Naito, S. Nakagawa, and K. Fujisawa. 1972. BB-K 8, a new semisynthetic aminoglycoside. J. Antibiot. (Tokyo) 25:695-708.
44. Kobayashi, Y., and T. Tsuchiya. 1997. Synthesis of 2″-oxidized derivatives of 5-deoxy-5-epi-5-fluoro-dibekacin and -arbekacin, and study on structure-chemical shift relationships of urethane (or amide)-type NH protons in synthetic intermediates. Carbohydr. Res. 298:261-277.
45. Kondo, S., K. Jinuma, H. Yamamoto, K. Maeda, and H. Umezawa. 1973. Syntheses of 1-N-(S)-4-amino-2-hydroxybutyryl-kanamycin B and-3′,4′-dideoxykanamycin B active against kanamycin-resistant bacteria. J. Antibiot. (Tokyo) 26:412-415.
46. Kondo, S., S. Shibahara, T. Usui, T. Kudo, A. Tamura, S. Gomi, and T. Takeuchi. 1993. New 2″-amino derivatives of arbekacin, potent aminoglycoside antibiotics against methicillin-resistant Staphylococcus aureus. J. Antibiot. (Tokyo) 46:531-534.
47. Kondo, S., A. Tamura, S. Gomi, Y. Ikeda, T. Takeuchi, and S. Mitsuhashi. 1993. Structures of enzymatically modified products of arbekacin by methicillin-resistant Staphylococcus aureus. J. Antibiot. (Tokyo) 46:310-315.
48. Kotretsou, S., M.-P. Mingeot-Leclercq, V. Constantinou-Kokotou, R. Brasseur, M. P. Georgiadis, and P. M. Tulkens. 1995. Synthesis and antimicrobial and toxicological studies of amino acid and peptide derivatives of kanamycin A and netilmicin. J. Med. Chem. 38:4710-4719.
49. Kurebe M., M. Yokota, T. Niizato, F. Kai, T. Yoshida, R. Okamoto, and S. Mitsuhashi. 1986. Antibacterial activity and ototoxicity in guinea pigs, and nephrotoxicity in rats of arbekacin. Arzneim-Forsch. 36:1511-1517.
50. Kuwahara, R., and T. Tsuchiya. 1996. Synthesis of dibekacin analogs containing 3-oxa- and 3-aza-2,3,4,-trideoxy-D-glycero-hexopyranose. Carbohydr. Res. 293:15-20.
51. 13C NMR. Carbohydr. Res. 299:271-279.
52. Li, K., M. Fernandez-Saiz, C. T. Rigl, A. Kumar, K. G. Ragunathan, A. W. McConnaughie, and W. D. Wilson. 1997. Design and analysis of molecular motifs for specific recognition of RNA. Bioorg. Med. Chem. 5:1157-1172.
53. Loebenberg, D., M. Counelis, and J. A. Waitz. 1975. Antibiotic G-418, a new Micromonospora-produced aminoglycoside with activity against protozoa and helminths: antiparasitic activity. Antimicrob. Agents Chemother. 7:811-815.
54. Loibner, H., W. Streicher, and P. Stütz. 5 March 1985. European patent application US1982000404817.
55. Lynch, C., P. Courvalin, and H. Nikaido. 1997. Active efflux of antimicrobial agents in wild-type strains of Enterococci. Antimicrob. Agents Chemother. 41:869-871.
56. MacArthur, R. D., V. T. Lolans, F. A. Zar, and G. G. Jackson. 1984. Biphasic, concentration-dependent and rate-limited, concentration-independent bacterial killing by an aminoglycoside antibiotic. J. Infect. Dis. 150:778-779.
57. McKay, G. A., and G. D. Wright. 1995. Kinetic mechanism of aminoglycoside phosphotransferase type IIIa. J. Biol. Chem. 270:24686-24692.
58. McKay, G. A., R. A. Robinson, W. S. Lane, and G. D. Wright. 1994. Activesite landing of an aminoglycoside antibiotic phosphotransferase APH(3′)-IIIa. Biochemistry 33:14115-14120.
59. McKay, G. A., J. Roestamadji, S. Mobashery, and G. D. Wright. 1996. Recognition of aminoglycoside antibiotics by enterococcal-staphylococcal aminoglycoside 3′-phosphotransferase type IIIa: role of substrate amino groups. Antimicrob. Agents Chemother. 40:2648-2650.
60. McKay, G. A., P. R. Thompson, and G. D. Wright. 1994. Broad spectrum aminoglycoside phosphotransferase type III from Enterococcus: overexpression, purification and substrate specificity. Biochemistry 33:6936-6944.
61. Melancon, P., W. E. Tapprich, and L. Brakier-Gingras. 1992. Single-base mutations at position 2661 of Escherichia coli 23S rRNA increase efficiency of translational proofreading. J. Bacteriol. 174:7896-7901.
62. Menard, R., C. Molinas, M. Arthur, J. Duval, P. Courvalin, and R. Leclercq. 1993. Overproduction of 3′-aminoglycoside phosphotransferase type I confers resistance to tobramycin in Escherichia coli. Antimicrob. Agents Chemother. 37:78-83.
63. Miller, G. H., F. J. Sabatelli, R. S. Hare, and Y. Glupczynski. 1997. The most frequent aminoglycoside resistance mechanism - changes with time and geographic area: a reflection of aminoglycoside usage patterns? Clin. Infect. Dis. 24:S46-S62.
64. Miller, G. H., F. J. Sabatelli, L. Naples, R. S. Hare, and K. J. Shaw. 1995. The changing nature of aminoglycoside resistance mechanisms and the role of isepamicin - a new broad-spectrum aminoglycoside. J. Chemother. 7:31-44.
65. Miller, G. H., F. J. Sabatelli, L. Naples, R. S. Hare, and K. J. Shaw. 1995. The most frequently occurring aminoglycoside resistance mechanisms -combined results of surveys in eight regions of the world. J. Chemother. 7:17-30.
66. Miller, G. H. Personal communication.
67. Mingeot-Leclercq, M. P., and P. M. Tulkens. 1999. Aminoglycosides: Nephrotoxicity. Antimicrob. Agents Chemother., in press.
68. Mitsuhashi, S., and H. Kawade. 1982. Aminoglycoside antibiotic resistance in bacteria, p. 97-122. In A. Whelton and H. C. Neu (ed.), The aminoglycosides. Microbiology, clinical use and toxicity. Marcel Dekker, Inc., New York, N.Y.
69. Miyaguchi, H., H. Narita, K. Sakamoto, and S. Yokoyama. 1996. An antibiotic-binding motif of an RNA fragment derived from the A-site-related region of Escherichia coli 16S rRNA. Nucleic Acids Res. 24:3700-3706.
70. Miyake, T., T. Tsuchiya, S. Umezawa, and H. Umezawa. 1976. Synthesis of 3′,4′-dideoxykanamycin B. Carbohydr. Res. 49:141-151.
71. Moellering, R. C., Jr. 1982. Clinical microbiology and the in vitro activity of aminoglycosides, p. 65-95. In A. Whelton and H. C. Neu (ed.), The aminoglycosides. Marcel Dekker, Inc., New York, N.Y.
72. Moore, R. D., P. S. Lietman, and C. R. Smith. 1987. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J. Infect. Dis. 155:93-99.
73. Murray, B. E. 1991. New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. J. Infect. Dis. 163:1185-1194.
74. Nagabhushan, T. L., A. B. Cooper, H. Tsai, P. J. L. Daniels, and G. H. Miller. 1978. The syntheses and biological properties of 1-N-((S)-4-amino-2-hydroxybutyryl)-gentamicin B and 1-N-((S)-3-amino-2-hydroxypropionyl)-gentamicin B. J. Antibiot. (Tokyo) 31:681-687.
75. Nagabhushan, T. L., G. H. Miller, and M. J. Weinstein. 1982. Structure-activity relationships in aminoglycoside-aminocyclitol antibiotics, p. 3-27. In A. Whelton and H. C. Neu (ed.), The aminoglycosides, Marcel Dekker, Inc., New York, N.Y.
76. Naito, T., S. Nakagawa, Y. Abe, S. Toda, K. Fujisawa, T. Miyaki, and H. Kawaguchi. 1973. Aminoglycoside antibiotics. II. Configurational and positional isomers of BB-K 8. J. Antibiot. (Tokyo) 26:297-301.
77. Nikaido, H. 1996. Multidrug efflux pumps of gram-negative bacteria. J. Bacteriol. 178:5853-5859.
78. Ohba, K., T. Tsuruoka, K. Mizutani, N. Kato, S. Omoto, N. Ezaki, and K. Watanabe. 1981. Studies on a new aminoglycoside antibiotic, dactimicin. II. Isolation, structure and chemical degradation. J. Antibiot. (Tokyo) 34: 1090-1100.
79. Okachi, R., I. Kawamoto, S. Takasawa, M. Yamamoto, S. Sato, T. Sato, and T. Nara. 1974. A new antibiotic XK-62-2 (sagamicin). I. Isolation, physicochemical and antibacterial properties. J. Antibiot. (Tokyo) 27:793-800.
80. Pearson, N. D., and C. D. Prescott. 1997. RNA as a drug target. Chem. Biol. 4:409-414.
81. Pedersen, L. C., M. M. Benning, and H. M. Holden. 1995. Structural investigation of the antibiotic and ATP-binding sites in kanamycin nucleotidyltransferase. Biochemistry 34:13305-13311.
82. Price, K. E. 1986. Aminoglycoside research 1975-1985: prospects for development of improved agents. Antimicrob. Agents Chemother. 29:543-548.
83. Price, K. E., J. C. Godfrey, and H. Kawaguchi. 1977. Effect of structural modifications on the biological properties of aminoglycoside antibiotics containing 2-deoxystreptamine, p. 239-355. In D. Perlman (ed.), Structure-activity relationships among the semi-synthetic antibiotics. Academic Press, New York, N.Y.
84. Price, K. E., P. A. Kresel, L. A. Farchione, S. B. Siskin, and S. A. Karpow. 1981. Epidemiological studies of aminoglycoside resistance in the USA. J. Antimicrob. Chemother. 8(Suppl. A):89-105.
85. Rather, P. N., H. Munayyer, P. A. Mann, R. S. Hare, G. H. Miller, and K. J. Shaw. 1992. Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6′-N-acetyltransferase-Ib and IIa proteins. J. Bacteriol. 174:3196-3203.
86. Rather, P. N., M. M. Parojcic, and M. R. Paradise. 1997. An extracellular factor regulating expression of the chromosomal aminoglycoside 2′-N-acetyltransferase of Providencia stuartii. Antimicrob. Agents Chemother. 41:1749-1754.
87. Roestamadji, J., I. Grapsas, and S. Mobashery. 1995. Mechanism-based inactivation of bacterial aminoglycoside 3′-phosphotransferases. J. Am. Chem. Soc. 117:80-84.
88. Roestamadji, J., I. Grapsas, and S. Mobashery. 1995. Loss of individual electrostatic interactions between aminoglycoside antibiotics and resistance enzymes as an effective means to overcoming bacterial drug resistance. J. Am. Chem. Soc. 117:11060-11069.
89. Sakon, J., H. H. Liao, A. M. Kanikula, M. M. Benning, I. Rayment, and H. M. Holden. 1993. Molecular structure of kanamycin nucleotidyltransferase determined to 3.0-Å resolution. Biochemistry 32:11977-11984.
90. Santerre, R. F., N. E. Allen, J. N. Hobbs, R. N. Rao, and R. J. Schmidt. 1984. Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells. Gene 30:147-156.
91. a. Schindler, J. 26 July 1997, posting date. Aminoglycoside-inactivating enzymes. [Online.] http://www.warn.cas.cz. [26 February 1999, last date accessed.]
92. Shaw, K. J., P. N. Rather, R. S. Hare, and G. H. Miller. 1993. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol. Rev. 57:138-163.
93. Shimizu, K., T. Kumada, R. S. Hare, G. H. Miller, F. J. Sabatelli, and G. Howard. 1985. Comparison of aminoglycoside resistance patterns in Japan. Formosa, and Korea, Chile and the United States. Antimicrob. Agents Chemother. 28:282-288.
94. Shitara, T., Y. Kobayashi, T. Tsuchiya, and S. Umezawa. 1992. Synthesis of 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of kanamycin B and its analogs. Study on structure-toxicity relationships. Carbohydr. Res. 232: 273-290.
95. Siregar, J. J., S. A. Lerner, and S. Mobashery. 1994. Purification and characterization of aminoglycoside 3′-phosphotransferase type IIa and kinetic comparison with a new mutant enzyme. Antimicrob. Agents Chemother. 38:641-647.
96. Siregar, J. J., K. Miroshnikov, and S. Mobashery. 1995. Purification, characterization, and investigation of the mechanism of aminoglycoside 3′-phosphotransferase type Ia. Biochemistry 34:12681-12688.
97. a. Stütz, P. Personal communication.
98. Takahashi, Y., T. Tsuchiya, S. Umezawa, and H. Umezawa. 1991. Synthesis of 3′-deoxy-3′-fluorokanamycin A and 3′,4′-dideoxy-3′-fluorokanamycin A. Carbohydr. Res. 210:221-232.
99. Takahashi, Y., S. Tsuneda, T. Tsuchiya, Y. Koyama, and S. Umezawa. 1992. Synthesis of 4′-deoxy-4′-fluorokanamycin A and B. Carbohydr. Res. 232: 89-105.
100. Takano, M., M. Okuda, M. Yasuhara, and R. Hori. 1994. Cellular toxicity of aminoglycoside antibiotics in G418-sensitive and -resistant LLC-PK1 cells. Pharm. Res. 11:609-615.
101. Tanaka, N., K. Matsunaga, A. Hirata, Y. Matsuhisa, and T. Nishimura. 1983. Mechanism of action of habekacin, a novel amino acid-containing aminoglycoside antibiotic. Antimicrob. Agents Chemother. 24:797-802.
102. Thompson, P. R., D. W. Hughes, and G. D. Wright. 1996. Mechanism of aminoglycoside 3′-phosphotransferase type IIIa: HIS188 is not a phosphate accepting residue. Chem. Biol. 3:747-755.
103. Tsuchiya, T., T. Shitara, S. Umezawa, T. Takeuchi, M. Hamada, N. Tomono, and E. Umemura. 1993. Synthesis of low-toxicity, 5-deoxy-5-fluoro and 5-deoxy-5,5-difluoro derivatives of arbekacin and its analogs, and study of structure-toxicity relationships. Carbohydr. Res. 240:307-312.
104. Tsuchiya, T., Y. Takahashi, Y. Kobayashi, S. Umezawa, and H. Umezawa. 1985. Synthesis of 3′-deoxy-3′-fluorokanamycins A and B active against resistant bacteria. J. Antibiot. (Tokyo) 38:1287-1290.
105. Tsuchiya, T., Y. Takahashi, Y. Kobayashi, S. Umezawa, and H. Umezawa. 1985. Synthesis of 2′,3′-dideoxy-2′-fluorokanamycin A. J. Carbohydr. Chem. 4:587-611.
106. Tsukiura, H., K. Fujisawa, M. Konishi, K. Saito, K. Numata, H. Ishikawa, and H. Kawaguchi. 1973. Aminoglycoside antibiotics. III. Bio-active degradation products from butirosins and semi-synthesis of butirosin analogs. J. Antibiot. (Tokyo) 26:351-357.
107. Tulkens, P., and A. Trouet. 1978. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem. Pharmacol. 27:415-424.
108. Ubukata, K., N. Yamashita, A. Gotoh, and M. Konno. 1984. Purification and characterization of aminoglycoside-modifying enzymes from Staphylococcus aureus and staphylococcus epidermidis. Antimicrob. Agents Chemother. 25:754-759.
109. Umemura, E., T. Tsuchiya, Y. Kobayashi, and K. Tanaka. 1992. A synthetic study of methyl 3-deoxy-3-fluoro-alpha-D-glucopyranosides from methyl 2,3-anhydro-alpha-D-allopyranosides, and synthesis of 3′-deoxy-3′-fluorokanamycin A and 3′-chloro-3′-deoxykanamycin A. Carbohydr. Res. 224: 141-163.
110. Umezawa, H., S. Umezawa, T. Tsuchiya, and Y. Okazaki. 1971. 3′,4′-dideoxykanamycin B active against kanamycin resistant Escherichia coli and Pseudomonas aeruginosa. J. Antibiot. (Tokyo). 24:485-487.
111. Umezawa, S., T. Tsuchiya, R. Muto, Y. Nishimura, and H. Umezawa. 1971. Synthesis of 3′-deoxykanamycin effective against kanamycin resistant Escherichia coli and Pseudomonas aeruginosa. J. Antibiot. (Tokyo) 24:274-275.
112. Vaara, M. 1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:395-411.
113. Van Schepdael, A., R. Busson, H. J. Vanderhaeghe, L. Verbist, P. J. Claes, M. P. Mingeot-Leclercq, and P. M. Tulkens. 1991. Synthesis, antibacterial activity and toxicological evaluation (in vitro and computer-aided) of 1-C-hydroxymethyl kanamycin B and 1-C-hydroxymethyl, 6″ chlorokanamycin B. J. Med. Chem. 34:1483-1492.
114. Wang, Y., K. Hamasaki, and R. R. Rando. 1997. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region. Biochemistry 36:768-779.
115. Woo, P. W. K., W. Dion, and Q. R. Bartz. 1971. Butirosins A and B, aminoglycoside antibiotics. III. Structures. Tetrahedron Lett. 2625-2628.
116. Wright, G. D., and P. Ladak. 1997. Overexpression and characterization of the chromosomal aminoglycoside 6′-N-acetyltransferase from Enterococcus faecium. Antimicrob. Agents Chemother. 41:956-960.
117. Wu, H. Y., G. H. Miller, M. G. Blanco, R. S. Hare, and K. J. Shaw. 1997. Cloning and characterization of an aminoglycoside 6′-N-acetyltransferase gene from Citrobacter freundii which confers an altered resistance profile. Antimicrob. Agents Chemother. 41:2439-2447.
118. Xiong, Y. Q., J. Caillon, H. Drugeon, G. Potel, and D. Baron. 1996. Influence of pH on adaptive resistance of Pseudomonas aeruginosa to aminoglycosides and their postantibiotic effects. Antimicrob. Agents Chemother. 40:35-39.
119. Xiong, Y.-Q., J. Caillon, M. F. Kergueris, H. Drugeon, D. Baron, G. Potel, and A. S. Bayer. 1997. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model. Antimicrob. Agents Chemother. 41:823-826.
120. Zapp, M. L., S. Stern, and M. R. Green. 1993. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74:969-978.
121. Zhanel, G. G., and W. A. Craig. 1994. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides. Clin. Pharmacokinet. 27: 377-399.